ANI Pharmaceuticals | ANIP - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
ANI Pharmaceuticals USD 124.18M 12.39M 2025-12
Aurora Cannabis CAD 29.79M 16.83M 2026-03
Canopy Growth CAD 8.26M 13.2M 2026-03
Eli Lilly USD 15.92B 1.33B 2025-12
Heron Therapeutics USD 29.47M 3.17M 2025-12
Hikma Pharmaceutical USD 362.5M 329.5M 2025-06
Knight Therapeutics CAD 64.72M 8.91M 2025-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Novartis USD 10.07B 758M 2026-03
Omeros USD -33.16M 18.52M 2024-06
Perrigo USD 325.5M 36.7M 2026-03
Sun Pharmaceuticals INR 125.24B 17.58B 2025-12
Teva Pharmaceutical Industries USD 2.11B 547M 2026-03